Can Probiotics Improve Symptoms and Quality of Life in People with Irritable Bowel Syndrome?

ffects of Probiotic Supplementation on Symptom Severity and Quality of Life in Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202607728633353

Enrollment

Registered

2026-07-24

Start date

2025-12-14

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

probiotic

placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age: Patients aged 18 to 64 years. Confirmed diagnosis: IBS diagnosed according to the Rome IV criteria, after exclusion of any organic disease. Digestive symptoms: Presence of digestive symptoms persisting for at least 6 months before diagnosis, including abdominal pain, bloating, and altered bowel habits. Informed consent: Ability to provide informed consent to participate in the study, understanding of the study objectives, and willingness to comply with the study schedule (visits, questionnaires, and treatment intake).

Exclusion criteria

Exclusion criteria: Other gastrointestinal disorders: Presence of an active or known organic gastrointestinal disease, including inflammatory bowel disease (Crohn's disease, ulcerative colitis), celiac disease, digestive cancer, or a history of major intestinal resection. Unexplored alarm symptoms: Rectal bleeding, significant unintentional weight loss, or unexplained anemia. Severe uncontrolled comorbidities: Severe heart failure, end-stage renal disease, or decompensated liver disease. Use of other supplements or medications: Recent use of medications affecting intestinal motility or the gut microbiota, or of other supplements that could interfere with the study results, such as probiotics. Pregnancy or breastfeeding. Psychiatric or cognitive disorders: Severe, unstabilized disorders affecting the patient's ability to complete questionnaires or follow study instructions.

Design outcomes

Primary

Measure	Time frame
Change in IBS symptom severity from baseline to one month, assessed using the [IBS Symptom Severity Scale (IBS-SSS)].	—

Secondary

Measure	Time frame
Change in quality of life from baseline to one month, assessed using the [IBS Quality of Life questionnaire (IBS-QoL)].	—

Countries

Tunisia

Contacts

Public Contactnour ncibi

Higher School of Health Sciences and Techniques of Tunis

nourncibi13@gmail.com+21693255510

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 10, 2026